Literature DB >> 15078179

HIV-specific CD8+ T cells: serial killers condemned to die?

Constantinos Petrovas1, Yvonne M Mueller, Peter D Katsikis.   

Abstract

An increasing body of evidence supports a key role for cytotoxic CD8+ T cells (CTL) in controlling HIV infection. Although a vigorous HIV-specific CD8+ T cell response is raised during the primary infection, these cells ultimately fail to control virus and prevent disease progression. The failure of CTL to control HIV infection has been attributed to a number of strategies HIV employs to evade the immune system. Recently, intrinsic defects in the CTL themselves have been proposed to contribute to the failure of CTL to control HIV. HIV-specific CD8+ T cells differ in their effector/memory phenotype from other virus-specific CD8+ T cells indicating that their differentiation status differs. This altered differentiation may affect effector functions as well as homing properties of these cells. Other studies have indicated that activation of HIV-specific CTL may be impaired and this contributes to their dysfunction. The effector function of these CTL may also be affected. There are conflicting reports about their ability to kill, whereas IFNgamma production does not appear to be impaired in these cells. In this review we focus on recent work indicating that apoptosis may be an important mechanism through which HIV evades the CTL response. In particular, HIV-specific CD8+ T cells are highly susceptible to CD95/Fas-induced apoptosis. This leads to the hypothesis that virus-specific cytotoxic T cells can be eliminated upon binding CD95L/FasL on HIV-infected cells. Understanding the intrinsic defects of CTL in HIV infection could lead to new therapeutic strategies and optimized vaccination protocols that enhance the HIV-specific cytotoxic response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15078179     DOI: 10.2174/1570162043484960

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  7 in total

Review 1.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

2.  Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.

Authors:  Sumathi Sankaran; Moraima Guadalupe; Elizabeth Reay; Michael D George; Jason Flamm; Thomas Prindiville; Satya Dandekar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-24       Impact factor: 11.205

3.  CD8+ cell depletion of SHIV89.6P-infected macaques induces CD4+ T cell proliferation that contributes to increased viral loads.

Authors:  Yvonne M Mueller; Duc H Do; Jean D Boyer; Muhamuda Kader; Joseph J Mattapallil; Mark G Lewis; David B Weiner; Peter D Katsikis
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

4.  Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion.

Authors:  Christine M Bucks; Jillian A Norton; Alina C Boesteanu; Yvonne M Mueller; Peter D Katsikis
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 5.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

6.  High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function.

Authors:  Maria Hottelet Foley; Talitha Forcier; Elizabeth McAndrew; Michael Gonzalez; Huabiao Chen; Boris Juelg; Bruce D Walker; Darrell J Irvine
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

7.  Transcriptomic meta-analysis identifies gene expression characteristics in various samples of HIV-infected patients with nonprogressive disease.

Authors:  Le-Le Zhang; Zi-Ning Zhang; Xian Wu; Yong-Jun Jiang; Ya-Jing Fu; Hong Shang
Journal:  J Transl Med       Date:  2017-09-12       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.